FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296879> ?p ?o ?g. }

• W4367296879 abstract "<h3>Objective:</h3> This real-world study characterises dosing/titration strategies among European physicians initiating solriamfetol and patient outcomes following initiation. <h3>Background:</h3> Excessive daytime sleepiness (EDS) is a symptom of narcolepsy that may be managed with wake-promoting agents or sodium oxybate. Solriamfetol (Sunosi™) is a dopamine/norepinephrine reuptake inhibitor approved to treat EDS associated with narcolepsy (75–150 mg/day). <h3>Design/Methods:</h3> This is an ongoing retrospective chart review conducted by physicians in Germany, France, and Italy. Data are reported from 70 German patients with narcolepsy. Eligible patients (≥18 years old, diagnosed with EDS due to narcolepsy, reached a stable solriamfetol dose, and completed ≥6 weeks of treatment) were classified into 3 groups based on solriamfetol initiation strategy: changeover (switched/switching from existing EDS medication[s]), add-on (added/adding to current EDS medication[s]), or new-to-therapy (no current/previous EDS medication). <h3>Results:</h3> Patients’ mean±SD age was 36.9±13.9 years. 56% were female. 57% experienced cataplexy. Anxiety/depression was the most frequently reported comorbidity (36%). Changeover was the most common initiation strategy (61%), followed by add-on (27%), then new-to-therapy (11%). The most common starting doses of solriamfetol were 75 (69%) and 150 mg/day (20%). Solriamfetol was titrated in 29 patients (41%), mostly within 7 days. Mean±SD Epworth Sleepiness Scale (ESS) score was 17.6±3.1 (n=61) at initiation and 13.6±3.8 at follow-up (n=51), with a mean decrease of 4.3±2.9 points. Improvements in EDS after solriamfetol initiation were reported for most patients (patient-reported, 91%; physician-reported, 94%). Most patients (72%) reported no change in perceived night-time sleep quality. Common adverse effects were headache, decreased appetite, and insomnia. No cardiovascular events were reported. <h3>Conclusions:</h3> These real-world data describe the use of solriamfetol in a cohort of German patients with narcolepsy. Solriamfetol was typically initiated at 75 mg/day; titration was common. ESS scores improved across subgroups; most patients and physicians perceived improvement in EDS. Common adverse events were consistent with those previously reported for solriamfetol. <b>Disclosure:</b> Dr. Winter has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bayer AG. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LivaNova. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz pharmaceuticals. Dr. Winter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bioprojet. Dr. Mayer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen, Idorsia, NLS Pharma. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia, Takeda. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Idorsia. Dr. Kotterba has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz. Dr. Kotterba has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bioprojet. Dr. Kotterba has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Kotterba has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for biogen. Heike Benes has nothing to disclose. Lothar Burghaus has nothing to disclose. Dr. Parks has received personal compensation for serving as an employee of Axsome Therapeutics. Dr. Parks has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Parks has stock in Axsome Therapeutics. Dr. Parks has stock in Jazz Pharmaceuticals. Dr. Koch has received personal compensation for serving as an employee of Jazz Pharmaceuticals Germany GmbH. Dr. Koch has stock in Jazz Pharmaceuticals. Daniela Girfoglio has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Daniela Girfoglio has stock in Jazz Pharmaceuticals. Ms. Setanoians has received personal compensation for serving as an employee of jazzpharmaceuticals. Ms. Setanoians has stock in jazzpharmaceuticals. Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AOP Orphan . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bioprojet . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AOP Orphan . Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bioprojet . Prof. Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz . Prof. Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony. Prof. Kallweit has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda . Prof. Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB ." @default.
• W4367296879 created "2023-04-29" @default.
• W4367296879 creator A5000431770 @default.
• W4367296879 creator A5000989945 @default.
• W4367296879 creator A5018576617 @default.
• W4367296879 creator A5020519718 @default.
• W4367296879 creator A5022083028 @default.
• W4367296879 creator A5047000315 @default.
• W4367296879 creator A5061165787 @default.
• W4367296879 creator A5073592911 @default.
• W4367296879 creator A5081848707 @default.
• W4367296879 creator A5088552578 @default.
• W4367296879 date "2023-04-25" @default.
• W4367296879 modified "2023-10-17" @default.
• W4367296879 title "Solriamfetol Real World Experience Study: Initiation, Titration, Safety, Effectiveness, and Experience During Follow-Up for Patients with Narcolepsy from Germany (P4-13.006)" @default.
• W4367296879 doi "https://doi.org/10.1212/wnl.0000000000203940" @default.
• W4367296879 hasPublicationYear "2023" @default.
• W4367296879 type Work @default.
• W4367296879 citedByCount "0" @default.
• W4367296879 crossrefType "proceedings-article" @default.
• W4367296879 hasAuthorship W4367296879A5000431770 @default.
• W4367296879 hasAuthorship W4367296879A5000989945 @default.
• W4367296879 hasAuthorship W4367296879A5018576617 @default.
• W4367296879 hasAuthorship W4367296879A5020519718 @default.
• W4367296879 hasAuthorship W4367296879A5022083028 @default.
• W4367296879 hasAuthorship W4367296879A5047000315 @default.
• W4367296879 hasAuthorship W4367296879A5061165787 @default.
• W4367296879 hasAuthorship W4367296879A5073592911 @default.
• W4367296879 hasAuthorship W4367296879A5081848707 @default.
• W4367296879 hasAuthorship W4367296879A5088552578 @default.
• W4367296879 hasConcept C118552586 @default.
• W4367296879 hasConcept C119599485 @default.
• W4367296879 hasConcept C126322002 @default.
• W4367296879 hasConcept C127413603 @default.
• W4367296879 hasConcept C187212893 @default.
• W4367296879 hasConcept C197934379 @default.
• W4367296879 hasConcept C2778205975 @default.
• W4367296879 hasConcept C2778664715 @default.
• W4367296879 hasConcept C2779034229 @default.
• W4367296879 hasConcept C2779494582 @default.
• W4367296879 hasConcept C2780129190 @default.
• W4367296879 hasConcept C2780163352 @default.
• W4367296879 hasConcept C2780714222 @default.
• W4367296879 hasConcept C2781326671 @default.
• W4367296879 hasConcept C558461103 @default.
• W4367296879 hasConcept C71924100 @default.
• W4367296879 hasConcept C761482 @default.
• W4367296879 hasConceptScore W4367296879C118552586 @default.
• W4367296879 hasConceptScore W4367296879C119599485 @default.
• W4367296879 hasConceptScore W4367296879C126322002 @default.
• W4367296879 hasConceptScore W4367296879C127413603 @default.
• W4367296879 hasConceptScore W4367296879C187212893 @default.
• W4367296879 hasConceptScore W4367296879C197934379 @default.
• W4367296879 hasConceptScore W4367296879C2778205975 @default.
• W4367296879 hasConceptScore W4367296879C2778664715 @default.
• W4367296879 hasConceptScore W4367296879C2779034229 @default.
• W4367296879 hasConceptScore W4367296879C2779494582 @default.
• W4367296879 hasConceptScore W4367296879C2780129190 @default.
• W4367296879 hasConceptScore W4367296879C2780163352 @default.
• W4367296879 hasConceptScore W4367296879C2780714222 @default.
• W4367296879 hasConceptScore W4367296879C2781326671 @default.
• W4367296879 hasConceptScore W4367296879C558461103 @default.
• W4367296879 hasConceptScore W4367296879C71924100 @default.
• W4367296879 hasConceptScore W4367296879C761482 @default.
• W4367296879 hasLocation W43672968791 @default.
• W4367296879 hasOpenAccess W4367296879 @default.
• W4367296879 hasPrimaryLocation W43672968791 @default.
• W4367296879 hasRelatedWork W2025559450 @default.
• W4367296879 hasRelatedWork W2073960829 @default.
• W4367296879 hasRelatedWork W2097842946 @default.
• W4367296879 hasRelatedWork W2314445782 @default.
• W4367296879 hasRelatedWork W2888946076 @default.
• W4367296879 hasRelatedWork W2919385085 @default.
• W4367296879 hasRelatedWork W3191590376 @default.
• W4367296879 hasRelatedWork W4290829952 @default.
• W4367296879 hasRelatedWork W4292110643 @default.
• W4367296879 hasRelatedWork W4318384130 @default.
• W4367296879 isParatext "false" @default.
• W4367296879 isRetracted "false" @default.
• W4367296879 workType "article" @default.